Home›Stock Screener›Panacea Biotec

Panacea Biotec Share Price Today | Stock Price & Panacea Biotec Share Screener

PANACEABIO Pharmaceuticals & Biotechnology
Live Share Price NSE
₹356.55
▲ 3.85 (1.09%)
2026-11-18 00:00:00
Live Share Price BSE
₹354.05
▲ 0.15 (0.04%)
2026-11-18 00:00:00

As of November 18, 2026, the live Panacea Biotec share price (NSE: PANACEABIO) is ₹356.55 on NSE and ₹354.05 on BSE, up 1.09% from the previous close, with shares trading between ₹344.20 and ₹362.45 in today's trading session, and a 52-week range of ₹296.05–₹607.75. Track Panacea Biotec market cap to gauge the company's total market size. Use the Panacea Biotec stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Panacea Biotec opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹199 and net income of ₹12, with EBITDA of ₹25, an operating margin of 8.0% and a profit margin of 6.0%.

Panacea Biotec Market Cap ₹2,153.58 Cr.
PANACEABIO P/E Ratio (TTM) -242.30
Panacea Biotec P/B Ratio 2.66
EPS (TTM) ₹-0.88
Dividend Yield -
Debt to Equity 0.02
PANACEABIO 52 Week High ₹607.75
Panacea Biotec 52 Week Low ₹296.05
Operating Margin 8.00%
Profit Margin 6.03%
PANACEABIO Revenue (TTM) ₹199.00
EBITDA ₹25.00
Net Income ₹12.00
Total Assets ₹1,262.00
Total Equity ₹829.00

Panacea Biotec Share Price Chart

Track the current stock price of Panacea Biotec with an interactive chart. Analyse PANACEABIO share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Panacea Biotec stock quote in one place.

The quote of ₹356.55 sits between the 52-week low of ₹296.05 and the 52-week high of ₹607.75, and the latest session moved 1.09% from the previous close.

Panacea Biotec Company Profile - Fundamental Screener

Screen Panacea Biotec company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for PANACEABIO shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE922B01023.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE922B01023

Panacea Biotec Balance Sheet Screener

Screen PANACEABIO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹1,262, down from ₹1,290 in 2025.

Latest statistics put total assets at ₹1,262 and shareholder funds at ₹829, with a leverage ratio of 0.02.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 1,262 1,290 1,241 1,271 1,759 1,178 1,390 1,376 1,608 1,800
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 576 567 582 600 622 609 657 806 949 1,001

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 85 92 94 101 109 960 739 90 611 846
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 829 831 838 840 874 -232 196 347 306 366
Share Capital 6 6 6 6 6 6 6 6 6 6
Reserves & Surplus 807 807 814 816 849 -257 139 335 293 340

Panacea Biotec Income Statement Screener - Profit & Revenue Analysis

Screen Panacea Biotec income statement and profit fundamentals. Analyze PANACEABIO quarterly results. Panacea Biotec reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹199 and net profit was ₹12, equal to earnings per unit of ₹1.90, at an operating margin of 8%.

In that period expenses were ₹174, interest cost ₹1 and tax ₹5. The next period listed, 2026-Jun, shows revenue of ₹207 and net profit of ₹2.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar

Revenue and Expenses

Revenue 199 207 172 170 150 184 169 170 155 122 150 159 149 163 163
Expenses 174 194 164 153 159 168 159 156 140 130 143 151 147 140 135

Operating Costs and Margins

EBITDA 25 13 8 17 -9 16 9 14 14 -8 8 8 2 24 29
Operating Profit % 8.00% 3.00% 2.00% 7.00% -13.00% -1.00% -20.00% 5.00% 5.00% -12.00% -4.00% 0.00% -2.00% -8.00% -4.00%
Depreciation 7 8 8 8 8 8 8 9 9 9 9 9 9 10 10
Interest 1 1 1 2 2 1 1 1 1 1 1 1 1 1 1

Profit and Earnings

Profit Before Tax 17 4 -1 7 -19 7 0 4 5 -17 -2 -2 -8 13 18
Tax 5 1 0 3 -5 3 2 0 0 -1 0 1 1 2 31
Net Profit 12 2 -1 4 -14 4 -2 4 5 -16 -2 -2 -8 11 -13
EPS 1.90 0.38 0.08 0.65 -2.27 0.66 -0.31 0.74 0.77 -2.59 -0.23 -0.37 -1.35 1.79 -2.03

Panacea Biotec Cash Flow Screener - Liquidity Fundamentals

Screen PANACEABIO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹17, and net cash flow was an outflow of ₹25.

Over the same period, investing activities used ₹41 and financing activities used ₹1.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 17 -27 0 -423 -108 107 -31 105 118 131
Investing Activities -41 65 10 430 1,283 -48 -35 -6 55 -26

Financing and Net Cash

Financing Activities -1 -3 -3 -18 -1,176 -47 91 -101 -164 -107
Net Cash Flow -25 35 7 -11 -2 12 26 -2 9 -2

Panacea Biotec Shareholding Pattern Screener

See Panacea Biotec shareholding pattern with promoter, FII, and DII holdings. Check Panacea Biotec promoter holding and ownership changes for PANACEABIO on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 72.48%, foreign institutions 1.60%, domestic institutions 1.97% and the public 16.81%, spread across 32,620 shareholders.

The shareholder count was 32,620 in 2026-Mar, compared with 33,532 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 72.48% 72.48% 72.48% 72.48% 72.48% 72.48% 72.48% 73.59%

Institutional Investors

FII Holding 1.60% 2.31% 2.75% 1.16% 0.78% 1.06% 1.36% 0.27%
DII Holding 1.97% 2.25% 2.47% 1.49% 1.52% 1.81% 1.85% 0.84%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 16.81% 15.54% 15.69% 18.45% 18.17% 17.69% 17.49% 19.90%
Other Holding 7.15% 7.42% 6.61% 6.41% 7.05% 6.96% 6.81% 5.40%
Shareholder Count 32,620 33,532 32,961 33,593 34,256 33,593 34,597 46,242

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Panacea Biotec. Panacea Biotec dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Panacea Biotec.

Panacea Biotec Stock Index Membership - Nifty & Sensex

See which indices include Panacea Biotec stock. Check PANACEABIO index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Panacea Biotec is not part of any tracked indices.
Only major market indices are tracked in our system.

Panacea Biotec Market Events Screener - Corporate Actions

Get Panacea Biotec corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Panacea Biotec stock events that may affect PANACEABIO share price, along with derivatives, futures and options activity and sector gainers.

13 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 14, 2026, with a record date of November 14, 2026.

It is followed by Annual General Meeting dated September 29, 2026 and Quarterly Result Announcement dated August 13, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-14 2026-11-14 Quarterly Result Announcement NA 2.61%
2026-09-29 2026-09-29 Annual General Meeting NA -11.03%
2026-08-13 2026-08-13 Quarterly Result Announcement NA -3.21%
2026-05-30 2026-05-30 Quarterly Result Announcement NA -1.53%
2026-02-11 2026-02-11 Quarterly Result Announcement NA 2.36%
2025-11-14 2025-11-14 Quarterly Result Announcement NA -6.47%
2025-09-30 2025-09-30 Annual General Meeting NA -4.67%
2025-08-14 2025-08-14 Quarterly Result Announcement NA 7.49%
2025-05-30 2025-05-30 Quarterly Result Announcement NA -1.52%
2025-02-14 2025-02-14 Quarterly Result Announcement NA 5.62%
2024-11-13 2024-11-13 Quarterly Result Announcement NA 12.32%
2024-11-12 2024-11-12 Quarterly Result Announcement NA 0.00%
2024-09-27 2024-09-27 Annual General Meeting NA -17.99%

Panacea Biotec Competitors Screener - Peer Stocks Comparison

Screen PANACEABIO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,076 41.10 61,674 12.69% 11,565 63.60
Divis Laboratories 294,139 90.70 11,067 13.95% 2,568 78.53
Torrent Pharmaceuticals 178,438 84.50 13,886 20.34% 2,138 47.27
Laurus Labs 119,949 98.10 6,868 22.01% 890 69.60
Zydus Life Science 118,902 27.60 27,658 17.64% 5,026 52.34
Dr Reddys Laboratories 115,011 41.70 35,059 3.90% 4,158 70.24
Cipla 112,656 39.40 29,045 2.24% 3,870 54.92
Mankind Pharma 108,490 48.40 14,636 14.85% 1,938 65.43
Aurobindo Pharma 103,223 26.40 34,145 5.56% 3,503 66.06
Lupin 90,393 17.30 29,039 26.75% 5,356 44.92

Panacea Biotec Company Announcements - News & Reports Screener

Screen PANACEABIO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated .

The next most recent announcements are dated November 19, 2026 and November 19, 2026.

Date Update Actions
Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-19 Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half-Year Ended September 30 2026 -
2026-11-19 Board Meeting Outcome for Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half-Year Ended September 30 2026 -
2026-11-11 Details Of Shares Dematerialized During October 2026 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations 2018 -
2026-11-10 Board Meeting Intimation for Approval Of Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter And Half Year Ended September 30 2026 -
2026-10-09 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-07 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-07 Details Of Shares Dematerialized During September 2026 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations 2018 -
2026-10-01 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-10-01 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-29 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-29 Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI LODR Regulations) -
2026-09-26 Receipt Of Demand Orders From The Office Of The Assistant Commissioner Of Income Tax Delhi -
2026-09-26 Closure of Trading Window -
2026-09-15 Communication Sent To Physical Shareholders To Furnish PAN And KYC Details -
2026-09-08 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-07 Book Closure For Annual General Meeting -
2026-09-07 Confirmation On Letter Being Sent To The Concerned Shareholders Providing The Weblink For Accessing The Annual Report For Financial Year 2025-26 And The Notice Of The Ensuing AGM To Be Held On September 29 2026 Through Video Conferencing / Other Audio-Vis -
2026-09-07 Business Responsibility and Sustainability Reporting (BRSR) -
2026-09-07 Reg. 34 (1) Annual Report. -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹356.55, within a 52-week range of ₹296.05 to ₹607.75. The P/E ratio is -242.30 and the P/B ratio is 2.66, with earnings per unit of ₹-0.88. Market capitalisation stands at ₹2,153.58 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.